Date: 2011-11-28
Type of information: Grant
Company: Targovax (Norway)
Investors: Innovation Norway OFU-program (Norway)
Amount: 9 million NOK (€1.1 million)
Funding type: grant
Planned used: This grant will be used to initiate a phase II/III clinical study of TG01 in operable pancreatic cancer. TG01 is a cancer vaccine which activates the body’s own immune system to recognize and kill cancer cells which have a mutated RAS-molecule.
Others: Targovax AS will receive 9 million NOK in support from the Innovation Norway OFU-program to develop a therapeutic cancer vaccine targeting operated pancreatic cancer. The company will develop the vaccine in collaboration with Oslo University Hospital, The Radium Hospital.
Therapeutic area: Cancer - Oncology
